Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamid Maadi

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cells|December 23, 2022
A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer CellsHamid Maadi, Zhixiang Wang
Cancers|September 23, 2018
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast CancerBabak Nami, Hamid Maadi, Zhixiang Wang
Methods in Molecular Biology (Clifton, N.J.)|August 10, 2017
Dimerization Assessment of Epithelial Growth Factor Family of Receptor Tyrosine Kinases by Using Cross-Linking ReagentHamid Maadi, Babak Nami, Zhixiang Wang
Scientific Reports|December 4, 2025
Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatmentAysan Shekari, Yaghub Pazhang, Hamid Maadi
Cancers|March 20, 2019
The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and PhosphorylationBabak Nami, Hamid Maadi, Zhixiang Wang
Methods in Molecular Biology (Clifton, N.J.)|August 31, 2022
Analysis of Cell Cycle by Flow CytometryHamid Maadi, Mohammad Hasan Soheilifar, Zhixiang Wang
BMC Cancer|March 2, 2018
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2Hamid Maadi, Babak Nami, Junfeng Tong, et al.
Environmental Toxicology and Pharmacology|December 25, 2012
Toxicity of ZnO nanoparticles in healthy adult miceMohammad Esmaeillou, Mohammad Moharamnejad, Ramin Hsankhani, et al.
Cancers|July 24, 2021
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a DilemmaHamid Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, et al.
The FEBS Journal|May 6, 2024
Overcoming retinoic acid resistance in HER2-enriched breast cancers: role of MYCWon-Shik Choi, Rong-Zong Liu, Caitlin Mak, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cells|December 23, 2022
A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer CellsHamid Maadi, Zhixiang Wang
Cancers|September 23, 2018
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast CancerBabak Nami, Hamid Maadi, Zhixiang Wang
Methods in Molecular Biology (Clifton, N.J.)|August 10, 2017
Dimerization Assessment of Epithelial Growth Factor Family of Receptor Tyrosine Kinases by Using Cross-Linking ReagentHamid Maadi, Babak Nami, Zhixiang Wang
Scientific Reports|December 4, 2025
Activation of TP53 target genes in the primary response of triple-negative breast cancer cells to doxorubicin treatmentAysan Shekari, Yaghub Pazhang, Hamid Maadi
Cancers|March 20, 2019
The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and PhosphorylationBabak Nami, Hamid Maadi, Zhixiang Wang
Methods in Molecular Biology (Clifton, N.J.)|August 31, 2022
Analysis of Cell Cycle by Flow CytometryHamid Maadi, Mohammad Hasan Soheilifar, Zhixiang Wang
BMC Cancer|March 2, 2018
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2Hamid Maadi, Babak Nami, Junfeng Tong, et al.
Environmental Toxicology and Pharmacology|December 25, 2012
Toxicity of ZnO nanoparticles in healthy adult miceMohammad Esmaeillou, Mohammad Moharamnejad, Ramin Hsankhani, et al.
Cancers|July 24, 2021
Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a DilemmaHamid Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, et al.
The FEBS Journal|May 6, 2024
Overcoming retinoic acid resistance in HER2-enriched breast cancers: role of MYCWon-Shik Choi, Rong-Zong Liu, Caitlin Mak, et al.
Pageof 2